JP2005501108A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501108A5
JP2005501108A5 JP2003522525A JP2003522525A JP2005501108A5 JP 2005501108 A5 JP2005501108 A5 JP 2005501108A5 JP 2003522525 A JP2003522525 A JP 2003522525A JP 2003522525 A JP2003522525 A JP 2003522525A JP 2005501108 A5 JP2005501108 A5 JP 2005501108A5
Authority
JP
Japan
Prior art keywords
stroke
post
composition according
treatment
neurodegeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003522525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501108A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2001/007180 external-priority patent/WO2003018005A1/en
Publication of JP2005501108A publication Critical patent/JP2005501108A/ja
Publication of JP2005501108A5 publication Critical patent/JP2005501108A5/ja
Pending legal-status Critical Current

Links

JP2003522525A 2001-08-22 2001-08-22 神経変性治療におけるネフィラセタムの使用 Pending JP2005501108A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/007180 WO2003018005A1 (en) 2001-08-22 2001-08-22 use of nefiracetam for treating neurodegeneration

Publications (2)

Publication Number Publication Date
JP2005501108A JP2005501108A (ja) 2005-01-13
JP2005501108A5 true JP2005501108A5 (enExample) 2008-10-16

Family

ID=11737657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003522525A Pending JP2005501108A (ja) 2001-08-22 2001-08-22 神経変性治療におけるネフィラセタムの使用

Country Status (8)

Country Link
US (2) US20040192759A1 (enExample)
EP (1) EP1420782B1 (enExample)
JP (1) JP2005501108A (enExample)
AT (1) ATE404192T1 (enExample)
CA (1) CA2457982C (enExample)
DE (1) DE60135390D1 (enExample)
ES (1) ES2311537T3 (enExample)
WO (1) WO2003018005A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
RU2329804C2 (ru) * 2006-03-28 2008-07-27 Валентина Ивановна Ахапкина Вещество, обладающее нейротропной - нейромодуляторной активностью
BRPI0920342A2 (pt) * 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
US8962676B2 (en) 2009-10-22 2015-02-24 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with CNS or PNS demyelination
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
JP3388778B2 (ja) * 1991-05-02 2003-03-24 第一製薬株式会社 脳血管性痴呆改善剤
AU8131198A (en) * 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
RU2001128504A (ru) Композиции для стимулирования роста
EP1651195A4 (en) PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
JP2002532432A5 (enExample)
RU2004136853A (ru) (s)-4-амино-5-хлор-2-метокси-n-[1-[1-(2-тетрагидрофурилкарбонил)-4- пиперидини лметил]-4-пиперидинил]бензамид, способ его получения, содержащая его фармацевтическая композиция и промежуточное соединение для его получения
JP2005507892A5 (enExample)
JP2005501108A5 (enExample)
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
JP2004537500A5 (enExample)
JP2006504735A5 (ja) 絨毛性性腺刺激ホルモンを含む慢性骨盤疼痛症候群の治療用組成物
RU2006113366A (ru) Терапевтическое лечение
JP2002537232A5 (enExample)
JP2005513036A5 (enExample)
JP2003522147A5 (enExample)
JP2002537256A5 (enExample)
JP2003523385A5 (enExample)
JP2002537246A5 (enExample)
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
JP2002501021A5 (enExample)
CA2368352A1 (en) Method for treating neurodegeneration
RU2002122703A (ru) Способ лечения воспалительных и воспалительно-деструктивных заболеваний пародонта
JP2004262775A5 (enExample)
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
Clifford et al. Occlusal splint prescription in the management of temporomandibular disorders
TW200505427A (en) A solid oral dosage form of metformin and glyburide and the method of preparation thereof